1910 AI Biotechnology (1910 Genetics) is a biotech company focused on leveraging artificial intelligence and automation to accelerate drug discovery, with its core being the ITO™ AI-powered platform.
The platform mainly supports end-to-end drug discovery from target identification to lead compound optimization, covering design, virtual screening, and optimization for both small molecules and large molecules (such as antibodies).
Three main collaboration models: embedding ITO infrastructure, joint engineering development, and joint discovery collaborations from design to candidate drug delivery.
The core value lies in significantly shortening the drug development cycle, reducing R&D costs, and increasing success rates for hard-to-drug targets.
The pipeline focuses on three main therapeutic areas: precision oncology, immunology and inflammation, and precision neuroscience.
The platform is trained on large-scale biochemical databases (such as ChEMBL and ZINC) and integrates multimodal data with state-of-the-art AI models to improve predictive and generative accuracy.
C3 AI is a leading enterprise AI software provider offering an integrated AI platform and industry-specific applications to help businesses accelerate digital transformation, optimize operations, and make data-driven decisions.
Tempus AI is a precision medicine company that uses artificial intelligence and data platforms to integrate multimodal medical data, delivering data-driven solutions for clinical decision support, medical research and drug development.
